Last week, during our inaugural Ars Live event, Quilty Space director of research Caleb Henry joined Ars space editor Eric Berger for a discussion of SpaceX’s Starlink and other satellite internet systems. We discussed Starlink’s rapid road to profitability—it took just five years from the first launch of operational satellites—and the future of the technology.
One of the keys to Starlink’s success is its vertical integration as a core business at SpaceX, which operates the world’s only reusable rocket, the Falcon 9. This has allowed the company not just to launch a constellation of 6,000 satellites—but to do so at relatively low cost.
“At one point, SpaceX had publicly said that it was $28 million,” Henry said of the company’s target for a Falcon 9 launch cost. “We believe today that they are below $20 million per launch and actually lower than that… I would put it in the mid teens for how much it costs them internally. And that’s going down as they increase the reuse of the vehicle. Recently, they’ve launched their 20th, maybe 21st, use of a first-stage rocket. And as they can amortize the cost of the booster over a greater number of missions, that only helps them with their business case.”
SpaceX was founded as a launch company in 2002, first with the Falcon 1 and then the Falcon 9 and Falcon Heavy rockets. But it is clear today that a significant portion of the company’s revenue, if not a majority, comes from its Starlink satellite internet business. So is it still primarily a rocket company?
“I think today they’re a satellite communications company,” Henry said of SpaceX. “I think it’s interesting that Stéphane Israël from Arianespace—in the early days, like 2015, 2016 when Starlink was just announced—would try to court customers and say, ‘Do you want to fund your competitor?’ And no one really took him seriously. Now people are taking him very seriously. [SpaceX is] the largest satellite operator in the world. They have literally more than doubled the number of consumer subscribers for satellite internet in the world.. This is a humongous, nearly unrivaled impact that they’ve had on the industry.”
Please find our entire discussion in the video above, complete with a transcript.
Enlarge/ Boeing’s Starliner spacecraft approaches the International Space Station on Thursday.
NASA TV
NASA and Boeing will take an additional four days to review all available data about the performance of the Starliner spacecraft before clearing the vehicle to return to Earth, officials said Tuesday.
Based on the new schedule, which remains pending ahead of final review meetings later this week, Starliner would undock at 10: 10 pm ET on Tuesday, June 25, from the International Space Station (02: 10 UTC on June 26). This would set up a landing at 4: 51 ET on June 26 (08: 51 UTC) at the White Sands Test Facility in New Mexico.
During a news conference on Tuesday, the program manager for NASA’s Commercial Crew Program, Steve Stich, said the four-day delay in the spacecraft’s return would “give our team a little bit more time to look at the data, do some analysis, and make sure we’re really ready to come home.”
Working two major issues
NASA is still trying to clear two major hardware issues that occurred during the spacecraft’s flight to the International Space Station nearly two weeks ago: five separate leaks in the helium system that pressurizes Starliner’s propulsion system and the failure of five of the vehicle’s 28 reaction-control system thrusters as Starliner approached the station.
Since then, engineers from NASA and Boeing have been studying these two problems. They took an important step toward better understanding both on Saturday, June 15, when Starliner was powered up for a thruster test.
During this test, engineers found that helium leak rates inside Starliner’s Service Module were lower than the last time the vehicle was powered on. Although the precise cause of the leak is not fully understood—it is possibly due to a seal in the flange between the thruster and manifold—the lower leak rate gave engineers confidence they could manage the loss of helium. Even before this decrease in the leak, Starliner had large reserves of helium, officials said.
The test of the reaction control system thrusters also went well, Stich said. Four of the five thrusters operated normally, and they are expected to be available for the undocking of Starliner later this month. These thrusters, which are fairly low-powered, are primarily used for small maneuvers. They will also be needed for the de-orbit burn that will set Starliner on its return path to Earth. Starliner can perform this burn without a full complement of thrusters, but Stich did not say how many could be safely lost.
First operational mission when?
NASA is being cautious about Starliner because this is the first crewed flight of the vehicle, which NASA funded to provide transportation services to the International Space Station. The goal is to provide regular flights of four astronauts to the space station for six-month rotations. This initial test flight, carrying NASA astronauts Butch Wilmore and Suni Williams, is intended to provide data to certify the vehicle for operational missions.
The first opportunity for Boeing to fly one of these operational missions is early 2025, likely in February or March. NASA will soon need to decide whether to give this slot to Starliner or SpaceX’s Dragon vehicle for the Crew-10 mission—NASA’s 10th operational flight on Dragon.
Given the technical problems that cropped up on the current test flight, it seems likely that NASA will push Starliner’s operational mission to the next available slot, likely in August or September of 2025. However, Stich said Tuesday no decision has been made and that NASA needs to study the results of this test flight.
“We haven’t looked too much ahead to Starliner-1,” he said. “We’ve got to go address the helium leaks. We’re not gonna go fly another mission like this with the helium leaks, and we’ve got to go understand what the rendezvous profile is doing that’s causing the thrusters to have low thrust, and then be deselected by the flight control team.”
Although Starliner’s first crewed flight has challenged NASA and Boeing, Stich said the process has not been frustrating. “I would not characterize it as frustration,” he said Tuesday. “I would characterize it as learning.”
Artist’s animation of the black hole at the center of SDSS1335+0728 awakening in real time—a first for astronomers.
In December 2019, astronomers were surprised to observe a long-quiet galaxy, 300 million light-years away, suddenly come alive, emitting ultraviolet, optical, and infrared light into space. Far from quieting down again, by February of this year, the galaxy had begun emitting X-ray light; it is becoming more active. Astronomers think it is most likely an active galactic nucleus (AGN), which gets its energy from supermassive black holes at the galaxy’s center and/or from the black hole’s spin. That’s the conclusion of a new paper accepted for publication in the journal Astronomy and Astrophysics, although the authors acknowledge the possibility that it might also be some kind of rare tidal disruption event (TDE).
The brightening of SDSS1335_0728 in the constellation Virgo, after decades of quietude, was first detected by the Zwicky Transient Facility telescope. Its supermassive black hole is estimated to be about 1 million solar masses. To get a better understanding of what might be going on, the authors combed through archival data and combined that with data from new observations from various instruments, including the X-shooter, part of the Very Large Telescope (VLT) in Chile’s Atacama Desert.
There are many reasons why a normally quiet galaxy might suddenly brighten, including supernovae or a TDE, in which part of the shredded star’s original mass is ejected violently outward. This, in turn, can form an accretion disk around the black hole that emits powerful X-rays and visible light. But these events don’t last nearly five years—usually not more than a few hundred days.
So the authors concluded that the galaxy has awakened and now has an AGN. First discovered by Carl Seyfert in 1943, the glow is the result of the cold dust and gas surrounding the black hole, which can form orbiting accretion disks. Gravitational forces compress the matter in the disk and heat it to millions of degrees Kelvin, producing radiation across the electromagnetic spectrum.
Alternatively, the activity might be due to an especially long and faint TDE—the longest and faintest yet detected, if so. Or it could be an entirely new phenomenon altogether. So SDSS1335+0728 is a galaxy to watch. Astronomers are already preparing for follow-up observations with the VLT’s Multi Unit Spectroscopic Explorer (MUSE) and Extremely Large Telescope, among others, and perhaps even the Vera Rubin Observatory slated to come online next summer. Its Large Synoptic Survey Telescope (LSST) will be capable of imaging the entire southern sky continuously, potentially capturing even more galaxy awakenings.
“Regardless of the nature of the variations, [this galaxy] provides valuable information on how black holes grow and evolve,” said co-author Paula Sánchez Sáez, an astronomer at the European Southern Observatory in Germany. “We expect that instruments like [these] will be key in understanding [why the galaxy is brightening].”
There is also a supermassive black hole at the center of our Milky Way galaxy (Sgr A*), but there is not yet enough material that has accreted for astronomers to pick up any emitted radiation, even in the infrared. So, its galactic nucleus is deemed inactive. It may have been active in the past, and it’s possible that it will reawaken again in a few million (or even billion) years when the Milky Way merges with the Andromeda Galaxy and their respective supermassive black holes combine. Only much time will tell.
Enlarge/ Lars Fruergaard Jorgensen, chief executive officer Novo Nordisk A/S, during an interview at the company’s headquarters in Bagsvaerd, Denmark, on Monday, June 12, 2023.
After some persuasion from Sen. Bernie Sanders (I-Vt.), the CEO of Novo Nordisk will testify before lawmakers later this year on the “outrageously high cost” of the company’s diabetes and weight-loss drugs—Ozempic and Wegovy—in the US.
CEO Lars Jørgensen will appear before the Senate Committee on Health, Education, Labor, and Pensions (HELP), which is chaired by Sanders, in early September. The agreement came after a conversation with Sanders in which the CEO reportedly “reconsidered his position” and agreed to testify voluntarily. As such, Sanders has canceled a vote scheduled for June 18 on whether to subpoena Novo Nordisk to discuss its US prices, which are considerably higher than those of other countries.
The independent lawmaker has been working for months to pressure Novo Nordisk into lowering its prices and appearing before the committee. In April, Sanders sent Jørgensen a letter announcing an investigation into the prices and included a lengthy set of information requests. In May, the committee’s investigation released a report suggesting that Novo Nordisk’s current pricing threatens to “bankrupt our entire health care system.”
Sanders has repeatedly hammered not only the high prices of Novo Nordisk’s two blockbuster drugs but also the huge disparity between US prices and those in other countries.
Up to 15x more in the US
“Novo Nordisk currently charges Americans with type 2 diabetes $969 a month for Ozempic, while this same exact drug can be purchased for just $155 in Canada and just $59 in Germany,” Sanders wrote in April. “Novo Nordisk also charges Americans with obesity $1,349 a month for Wegovy, while this same exact product can be purchased for just $140 in Germany and $92 in the United Kingdom.”
Yale researchers, meanwhile, published a study in JAMA in March estimating that both drugs could be manufactured for less than $5.
In May, Novo Nordisk responded with a letter to Sanders, arguing that blame for high prices in the US lies with the country’s complex health system and with middle managers who take cuts, according to Bloomberg. Novo Nordisk said in the letter that it is prepared to address “systemic issues so that everyone who can benefit from its medicines is able to get them,” the outlet reported. The company also said it has spent over $10 billion on research and development to bring Wegovy and Ozempic to the market.
Still, that number is small in comparison to the projected revenue from the drugs. Bloomberg noted that analysts estimate that Novo Nordisk will make $27 billion from the two drugs this year alone. The May analysis by the HELP committee found that if just half of the adults in the US with obesity start taking a new weight-loss drug, such as Wegovy, the collective cost would be around $411 billion per year. Another report by the Congressional Budget Office found that the drugs’ costs are so high that they will not be offset by any financial gains from improved health outcomes.
“The Committee looks forward to Mr. Jørgensen explaining why Americans are paying up to 10 or 15 times more for these medications than people in other countries,” Sanders said last week.
Enlarge/ Map from drone mission search for the Encephalartos Woodii in the Ngoye Forest in South Africa.
“Surely this is the most solitary organism in the world,” wrote paleontologist Richard Fortey in his book about the evolution of life.
He was talking about Encephalartos woodii (E. woodii), a plant from South Africa. E. woodii is a member of the cycad family, heavy plants with thick trunks and large stiff leaves that form a majestic crown. These resilient survivors have outlasted dinosaurs and multiple mass extinctions. Once widespread, they are today one of the most threatened species on the planet.
The only known wild E. Woodii was discovered in 1895 by the botanist John Medley Wood while he was on a botanical expedition in the Ngoye Forest in South Africa. He searched the vicinity for others, but none could be found. Over the next couple of decades, botanists removed stems and offshoots and cultivated them in gardens.
Fearing that the final stem would be destroyed, the Forestry Department removed it from the wild in 1916 for safekeeping in a protective enclosure in Pretoria, South Africa, making it extinct in the wild. The plant has since been propagated worldwide. However, the E. woodii faces an existential crisis. All the plants are clones from the Ngoye specimen. They are all males, and without a female, natural reproduction is impossible. E. woodii’s story is one of both survival and solitude.
My team’s research was inspired by the dilemma of the lonely plant and the possibility that a female may still be out there. Our research involves using remote sensing technologies and artificial intelligence to assist in our search for a female in the Ngoye Forest.
The evolutionary journey of cycads
Cycads are the oldest surviving plant groups alive today and are often referred to as “living fossils” or “dinosaur plants” due to their evolutionary history dating back to the Carboniferous period, approximately 300 million years ago. During the Mesozoic era (250-66 million years ago), also known as the Age of Cycads, these plants were ubiquitous, thriving in the warm, humid climates that characterised the period.
Although they resemble ferns or palms, cycads are not related to either. Cycads are gymnosperms, a group that includes conifers and ginkgos. Unlike flowering plants (angiosperms), cycads reproduce using cones. It is impossible to tell male and female apart until they mature and produce their magnificent cones.
Female cones are typically wide and round, and male cones appear elongated and narrower. The male cones produce pollen, which is carried by insects (weevils) to the female cones. This ancient method of reproduction has remained largely unchanged for millions of years.
Despite their longevity, today cycads are ranked as the most endangered living organisms on Earth with the majority of the species considered threatened with extinction. This is because of their slow growth and reproductive cycles, typically taking ten to 20 years to mature, and habitat loss due to deforestation, grazing, and over-collection. Cycads have become symbols of botanical rarity.
Their striking appearance and ancient lineage make them popular in exotic ornamental horticulture and that has led to illegal trade. Rare cycads can command exorbitant prices from $620 (495 pounds) per cm with some specimens selling for millions of pounds each. The poaching of cycads is a threat to their survival.
Among the most valuable species is the E. woodii. It is protected in botanical gardens with security measures such as alarmed cages designed to deter poachers.
AI in the sky
In our search to find a female E.woodii we have used innovative technologies to explore areas of the forest from a vertical vantage point. In 2022 and 2024, our drone surveys covered an area of 195 acres or 148 football fields, creating detailed maps from thousands of photos taken by the drones. It’s still a small portion of the Ngoye Forest, which covers 10,000 acres.
Enlarge/ An example of the still images used to train the AI software.
Our AI system enhanced the efficiency and accuracy of these searches. As E. woodii is considered extinct in the wild, synthetic images were used in the AI model’s training to improve its ability, via an image recognition algorithm, to recognise cycads by shape in different ecological contexts.
Plant species globally are disappearing at an alarming rate. Since all existing E. woodii specimens are clones, their potential for genetic diversity in the face of environmental change and disease is limited.
Notable examples include the Great Famine in 1840s Ireland, where the uniformity of cloned potatoes worsened the crisis, and the vulnerability of clonal Cavendish bananas to Panama disease, which threatens their production as it did with the Gros Michel banana in the 1950s.
Finding a female would mean E. woodii is no longer at the brink of extinction and could revive the species. A female would allow for sexual reproduction, bring in genetic diversity, and signify a breakthrough in conservation efforts.
E. woodii is a sobering reminder of the fragility of life on Earth. But our quest to discover a female E. woodii shows there is hope even for the most endangered species if we act fast enough.
A hammerhead shark less than one meter long swims frantically in a plastic container aboard a boat in the Sanquianga National Natural Park, off Colombia’s Pacific coast. It is a delicate female Sphyrna corona, the world’s smallest hammerhead species, and goes by the local name cornuda amarilla—yellow hammerhead—because of the color of its fins and the edges of its splendid curved head, which is full of sensors to perceive the movement of its prey.
Marine biologist Diego Cardeñosa of Florida International University, along with local fishermen, has just captured the shark and implanted it with an acoustic marker before quickly returning it to the murky waters. A series of receivers will help to track its movements for a year, to map the coordinates of its habitat—valuable information for its protection.
That hammerhead is far from the only shark species that keeps the Colombian biologist busy. Cardeñosa’s mission is to build scientific knowledge to support shark conservation, either by locating the areas where the creatures live or by identifying, with genetic tests, the species that are traded in the world’s main shark markets.
Sharks are under threat for several reasons. The demand for their fins to supply the mainly Asian market (see box) is a very lucrative business: Between 2012 and 2019, it generated $1.5 billion. This, plus their inclusion in bycatch—fish caught unintentionally in the fishing industry—as well as the growing market for shark meat, leads to the death of millions every year. In 2019 alone the estimated total killed was at least 80 million sharks, 25 million of which were endangered species. In fact, in the Hong Kong market alone, a major trading spot for shark fins, two-thirds of the shark species sold there are at risk of extinction, according to a 2022 study led by Cardeñosa and molecular ecologist Demian Chapman, director of the shark and ray conservation program at Mote Marine Laboratory in Sarasota, Florida.
Sharks continue to face a complicated future despite decades of legislation designed to protect them. In 2000, the US Congress passed the Shark Finning Prohibition Act, and in 2011 the Shark Conservation Act. These laws require that sharks brought ashore by fishermen have all their fins naturally attached and aim to end the practice of stripping the creatures of their fins and returning them, mutilated, to the water to die on the seafloor. Ninety-four other countries have implemented similar regulations.
Perhaps the main political and diplomatic tool for shark conservation is in the hands of the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES), composed of 183 member countries plus the European Union. The treaty offers three degrees of protection, or appendices, to more than 40,000 species of animals and plants, imposing prohibitions and restrictions on their trade according to their threat status.
Sharks were included in CITES Appendix II—which includes species that are not endangered but could become so if trade is not controlled—in February 2003, with the addition of two species: the basking shark (Cetorhinus maximus) and the whale shark (Rhincodon typus). Following that, the list of protected species grew to 12 and then increased significantly in November 2023 with the inclusion of 60 more species of sharks in CITES Appendix II.
But do these tools actually protect sharks? To seek out answers, over the past decade researchers have worked to develop tests that can easily identify which species of sharks are being traded—and determine whether protected species continue to be exploited. They have also focused on studying shark populations around the world in order to provide information for the establishment of protected areas that can help safeguard these animals.
The hydra is a Lovecraftian-looking microorganism with a mouth surrounded by tentacles on one end, an elongated body, and a foot on the other end. It has no brain or centralized nervous system. Despite the lack of either of those things, it can still feel hunger and fullness. How can these creatures know when they are hungry and realize when they have had enough?
While they lack brains, hydra do have a nervous system. Researchers from Kiel University in Germany found they have an endodermal (in the digestive tract) and ectodermal (in the outermost layer of the animal) neuronal population, both of which help them react to food stimuli. Ectodermal neurons control physiological functions such as moving toward food, while endodermal neurons are associated with feeding behavior such as opening the mouth—which also vomits out anything indigestible.
Even such a limited nervous system is capable of some surprisingly complex functions. Hydras might even give us some insights into how appetite evolved and what the early evolutionary stages of a central nervous system were like.
No, thanks, I’m full
Before finding out how the hydra’s nervous system controls hunger, the researchers focused on what causes the strongest feeling of satiety, or fullness, in the animals. They were fed with the brine shrimp Artemia salina, which is among their usual prey, and exposed to the antioxidant glutathione. Previous studies have suggested that glutathione triggers feeding behavior in hydras, causing them to curl their tentacles toward their mouths as if they are swallowing prey.
Hydra fed with as much Artemia as they could eat were given glutathione afterward, while the other group was only given only glutathione and no actual food. Hunger was gauged by how fast and how often they opened their mouths.
It turned out that the first group, which had already glutted themselves on shrimp, showed hardly any response to glutathione eight hours after being fed. Their mouths barely opened—and slowly if so—because they were not hungry enough for even a feeding trigger like glutathione to make them feel they needed seconds.
It was only at 14 hours post-feeding that the hydra that had eaten shrimp opened their mouths wide enough and fast enough to indicate hunger. However, those that were not fed and only exposed to glutathione started showing signs of hunger only four hours after exposure. Mouth opening was not the only behavior provoked by hunger since starved animals also somersaulted through the water and moved toward light, behaviors associated with searching for food. Sated animals would stop somersaulting and cling to the wall of the tank they were in until they were hungry again.
Food on the “brain”
After observing the behavioral changes in the hydra, the research team looked into the neuronal activity behind those behaviors. They focused on two neuronal populations, the ectodermal population known as N3 and the endodermal population known as N4, both known to be involved in hunger and satiety. While these had been known to influence hydra feeding responses, how exactly they were involved was unknown until now.
Hydra have N3 neurons all over their bodies, especially in the foot. Signals from these neurons tell the animal that it has eaten enough and is experiencing satiety. The frequency of these signals decreased as the animals grew hungrier and displayed more behaviors associated with hunger. The frequency of N3 signals did not change in animals that were only exposed to glutathione and not fed, and these hydra behaved just like animals that had gone without food for an extended period of time. It was only when they were given actual food that the N3 signal frequency increased.
“The ectodermal neuronal population N3 is not only responding to satiety by increasing neuronal activity, but is also controlling behaviors that changed due to feeding,” the researchers said in their study, which was recently published in Cell Reports.
Though N4 neurons were only seen to communicate indirectly with the N3 population in the presence of food, they were found to influence eating behavior by regulating how wide the hydras opened their mouths and how long they kept them open. Lower frequency of N4 signals was seen in hydra that were starved or only exposed to glutathione. Higher frequency of N4 signals were associated with the animals keeping their mouths shut.
So, what can the neuronal activity of a tiny, brainless creature possibly tell us about the evolution of our own complex brains?
The researchers think the hydra’s simple nervous system may parallel the much more complex central and enteric (in the gut) nervous systems that we have. While N3 and N4 operate independently, there is still some interaction between them. The team also suggests that the way N4 regulates the hydra’s eating behavior is similar to the way the digestive tracts of mammals are regulated.
“A similar architecture of neuronal circuits controlling appetite/satiety can be also found in mice where enteric neurons, together with the central nervous system, control mouth opening,” they said in the same study.
Enlarge/ Blue Origin’s New Glenn rocket on the launch pad for testing earlier this year.
After years of lobbying, protests, and bidding, Jeff Bezos’s space company is now a military launch contractor.
The US Space Force announced Thursday that Blue Origin will compete with United Launch Alliance and SpaceX for at least 30 military launch contracts over the next five years. These launch contracts have a combined value of up to $5.6 billion.
This is the first of two major contract decisions the Space Force will make this year as the military seeks to foster more competition among its roster of launch providers and reduce its reliance on just one or two companies.
For more than a decade following its formation from the merger of Boeing and Lockheed Martin rocket programs, ULA was the sole company certified to launch the military’s most critical satellites. This changed in 2018, when SpaceX started launching national security satellites for the military. In 2020, despite protests from Blue Origin seeking eligibility, the Pentagon selected ULA and SpaceX to continue sharing launch duties.
The National Security Space Launch (NSSL) program is in charge of selecting contractors to deliver military surveillance, navigation, and communications satellites into orbit.
Over the next five years, the Space Force wants to tap into new launch capabilities from emerging space companies. The procurement approach for this new round of contracts, known as NSSL Phase 3, is different from the way the military previously bought launch services. Instead of grouping all national security launches into one monolithic contract, the Space Force is dividing them into two classifications: Lane 1 and Lane 2.
The Space Force’s contract announced Thursday was for Lane 1, which is for less demanding missions to low-Earth orbit. These missions include smaller tech demos, experiments, and launches for the military’s new constellation of missile-tracking and data-relay satellites, an effort that will eventually include hundreds or thousands of spacecraft managed by the Pentagon’s Space Development Agency.
This fall, the Space Force will award up to three contracts for Lane 2, which covers the government’s most sensitive national security satellites, which require “complex security and integration requirements.” These are often large, heavy spacecraft weighing many tons and sometimes needing to go to orbits thousands of miles from Earth. The Space Force will require Lane 2 contractors to go through a more extensive certification process than is required in Lane 1.
“Today marks the beginning of this innovative, dual-lane approach to launch service acquisition, whereby Lane 1 serves our commercial-like missions that can accept more risk and Lane 2 provides our traditional, full mission assurance for the most stressing heavy-lift launches of our most risk-averse missions,” said Frank Calvelli, assistant secretary of the Air Force for space acquisition and integration.
Meeting the criteria
The Space Force received seven bids for Lane 1, but only three companies met the criteria to join the military’s roster of launch providers. The basic requirement to win a Lane 1 contract was for a company to show its rocket can place at least 15,000 pounds of payload mass into low-Earth orbit, either on a single flight or over a series of flights within a 90-day period.
The bidders also had to substantiate their plan to launch the rocket they proposed to use for Lane 1 missions by December 15 of this year. A spokesperson for Space Systems Command said SpaceX proposed using their Falcon 9 and Falcon Heavy rockets, and ULA offered its Vulcan rocket. Those launchers are already flying. Blue Origin proposed its heavy-lift New Glenn rocket, slated for an inaugural test flight no earlier than September.
“As we anticipated, the pool of awardees is small this year because many companies are still maturing their launch capabilities,” said Brig. Gen. Kristin Panzenhagen, program executive officer for the Space Force’s assured access to space division. “Our strategy accounted for this by allowing on-ramp opportunities every year, and we expect increasing competition and diversity as new providers and systems complete development.”
Enlarge/ A SpaceX Falcon Heavy rocket lifts off from NASA’s Kennedy Space Center in Florida.
Trevor Mahlmann/Ars Technica
The Space Force plans to open up the first on-ramp opportunity for Lane 1 as soon as the end of this year. Companies with medium-lift rockets in earlier stages of development, such as Rocket Lab, Relativity Space, Firefly Aerospace, and Stoke Space, will have the chance to join ULA, SpaceX, and Blue Origin in the Lane 1 pool at that time. The structure of the NSSL Phase 3 contracts allow the Pentagon to take advantage of emerging launch capabilities as soon as they become available, according to Calvelli.
In a statement, Panzenhagen said having additional launch providers will increase the Space Force’s “resiliency” in a time of increasing competition between the US, Russia, and China in orbit. “Launching more risk-tolerant satellites on potentially less mature launch systems using tailored independent government mission assurance could yield substantial operational responsiveness, innovation, and savings,” Panzenhagen said.
More competition, theoretically, will also deliver lower launch prices to the Space Force. SpaceX and Blue Origin rockets are partially reusable, while ULA eventually plans to recover and reuse Vulcan main engines.
Over the next five years, Space Systems Command will dole out fixed-price “task orders” to ULA, SpaceX, and Blue Origin for groups of Lane 1 missions. The first batch of missions up for awards in Lane 1 include seven launches for the Space Development Agency’s missile tracking mega-constellation, plus a task order for the National Reconnaissance Office, the government’s spy satellite agency. However, military officials require a rocket to have completed at least one successful orbital launch to win a Lane 1 task order, and Blue Origin’s New Glenn doesn’t yet satisfy this requirement.
The Space Force will pay Blue Origin $5 million for an “initial capabilities assessment” for Lane 1. SpaceX and ULA, the military’s incumbent launch contractors, will each receive $1.5 million for similar assessments.
ULA, SpaceX, and Blue Origin are also the top contenders to win Lane 2 contracts later this year. In order to compete in Lane 2, a launch provider must show it has a plan for its rockets to meet the Space Force’s stringent certification requirements by October 1, 2026. SpaceX’s Falcon 9 and Falcon Heavy are already certified, and ULA’s Vulcan is on a path to achieve this milestone by the end of this year, pending a successful second test flight in the next few months. A successful debut of New Glenn by the end of this year would put the October 2026 deadline within reach of Blue Origin.
Enlarge/ The payload fairing for the first test flight of Europe’s Ariane 6 rocket has been positioned around the small batch of satellites that will ride it into orbit.
Welcome to Edition 6.48 of the Rocket Report! Fresh off last week’s dramatic test flight of SpaceX’s Starship, teams in Texas are wasting no time gearing up for the next launch. Ground crews are replacing the entire heat shield on the next Starship spacecraft to overcome deficiencies identified on last week’s flight. SpaceX has a whole lot to accomplish with Starship in the next several months if NASA is going to land astronauts on the Moon by the end of 2026.
As always, we welcome reader submissions, and if you don’t want to miss an issue, please subscribe using the box below (the form will not appear on AMP-enabled versions of the site). Each report will include information on small-, medium-, and heavy-lift rockets as well as a quick look ahead at the next three launches on the calendar.
Virgin Galactic won’t be flying again any time soon. After an impressive but brief flurry of spaceflight activity—seven human spaceflights in a year, even to suborbital space, is unprecedented for a private company—Virgin Galactic will now be grounded again for at least two years, Ars reports. That’s because Colglazier and Virgin Galactic are betting it all on the development of a future “Delta class” of spaceships modeled on VSS Unity, which made its last flight to suborbital space Saturday. Virgin Galactic, founded by Richard Branson, now finds itself at a crossroads as it chases profitability, which VSS Unity had no hope of helping it achieve despite two decades of development and billions of dollars spent.
An uncertain future … Now, Virgin Galactic’s already anemic revenue numbers will drop to near zero as the company spends more capital to bring two Delta-class spaceships online. The goal is to start flying them in 2026. These vehicles are designed to be more easily reusable and carry six instead of four passengers. This timeline seems highly ambitious given that, at this point, the company is only developing tooling for the vehicles and won’t begin major parts fabrication until later this year. Virgin Galactic is betting on the Delta-class ships as its stock price has precipitously fallen over the last couple of years. In fact, Virgin Galactic announced a reverse stock split this week in a bid to maintain its listing on the New York Stock Exchange. (submitted by Ken the Bin)
Unpacking North Korea’s advancements in rocketry. Late last month, North Korea signaled it has made—or more accurately, is still trying to make—a pretty big leap in rocket technology. The isolated totalitarian state’s official news agency said it tested a new type of satellite launcher on May 27 powered by petroleum fuel and cryogenic liquid oxygen propellant. This is a radical change in North Korea’s rocket program, and it took astute outside observers by surprise. Previous North Korean rockets used hypergolic propellants, typically hydrazine and nitrogen tetroxide, or solid fuels, which are also well-suited for military ballistic missiles. Kerosene and liquid oxygen, on the other hand, aren’t great propellants for missiles but are good for a pure space launcher.
Who’s helping?… The May 27 launch failed shortly after liftoff, while the unnamed rocket was still in first stage flight over the Yellow Sea. But there is tangible and circumstantial evidence that Russia played a role in the launch. The details are still murky, but North Korean leader Kim Jong Un visited a Russian spaceport last September and met with Russian President Vladimir Putin, who suggested Russian help for the North’s satellite launch program was on the agenda at the summit. South Korean defense officials said Russian experts visited North Korea in the run-up to the May 27 launch. If Russia exported a kerosene-fueled rocket engine, or perhaps an entire booster, to North Korea, it wouldn’t be the first time Russia has shipped launch technology to the Korean Peninsula. Russia provided South Korea’s nascent space launch program with three fully outfitted rocket boosters for test flights in 2009, 2010, and 2023 before the South developed a fully domestic rocket on its own.
The easiest way to keep up with Eric Berger’s space reporting is to sign up for his newsletter, we’ll collect his stories in your inbox.
ABL signs deal with a new launch customer. ABL Space Systems, which is still trying to get its light launcher into orbit, has a new customer. Scout Space announced this week it has signed a launch agreement with ABL for the launch of a small spacecraft called “Owlet-01” on the third flight of ABL’s RS1 rocket, Space News reports. Scout Space, which describes itself as focused on space security and comprehensive space domain awareness, develops optical sensors to monitor the space environment. Owlet-01 will fly a telescope designed to detect other objects in space, a capability highly sought by the US military.
Still waiting on Flight 2 … The launch agreement between ABL and Space Scout is contingent on the outcome of the second flight of the RS1 rocket, which ABL has been preparing for the last few months. ABL hasn’t provided any public updates on the status of the second RS1 test flight since announcing in March that pre-flight preparations were underway at Kodiak Island, Alaska. The first RS1 rocket fell back on its launch pad in Alaska a few seconds after lifting off in January 2023. The RS1 is capable of hauling a payload of more than 1.3 metric tons to low-Earth orbit. (submitted by Ken the Bin)
Enlarge/ Ernest Shackleton died on board the Quest in 1922. Forty years later, the ship sank off Canada’s Atlantic Coast.
Tore Topp/Royal Canadian Geographical Society
Famed polar explorer Ernest Shackleton famously defied the odds to survive the sinking of his ship, Endurance, which became trapped in sea ice in 1914. His luck ran out on his follow-up expedition; he died unexpectedly of a heart attack in 1922 on board a ship called Quest. The ship survived that expedition and sailed for another 40 years, eventually sinking in 1962 after its hull was pierced by ice on a seal-hunting run. Shipwreck hunters have now located the remains of the converted Norwegian sealer in the Labrador Sea, off the coast of Newfoundland, Canada. The wreckage of Endurancewas found in pristine condition in 2022 at the bottom of the Weddell Sea.
The Quest expedition’s relatively minor accomplishments might lack the nail-biting drama of the Endurance saga, but the wreck is nonetheless historically significant. “His final voyage kind of ended that Heroic Age of Exploration, of polar exploration, certainly in the south,” renowned shipwreck hunter David Mearns told the BBC. “Afterwards, it was what you would call the scientific age. In the pantheon of polar ships, Quest is definitely an icon.”
As previously reported, Endurance set sail from Plymouth, Massachusetts, on August 6, 1914, with Shackleton joining his crew in Buenos Aires, Argentina. By January 1915, the ship had become hopelessly locked in sea ice, unable to continue its voyage. For 10 months, the crew endured the freezing conditions, waiting for the ice to break up. The ship’s structure remained intact, but by October 25, Shackleton realized Endurance was doomed. He and his men opted to camp out on the ice some two miles (3.2 km) away, taking as many supplies as they could with them.
Compacted ice and snow continued to fill the ship until a pressure wave hit on November 13, crushing the bow and splitting the main mast—all of which was captured on camera by crew photographer Frank Hurley. Another pressure wave hit in late afternoon November 21, lifting the ship’s stern. The ice floes parted just long enough for Endurance to finally sink into the ocean, before closing again to erase any trace of the wreckage.
When the sea ice finally disintegrated in April 1916, the crew launched lifeboats and managed to reach Elephant Island five days later. Shackleton and five of his men set off for South Georgia the next month to get help—a treacherous 720-mile journey by open boat. A storm blew them off course, and they ended up landing on the unoccupied southern shore. So Shackleton left three men behind while he and a companion navigated dangerous mountain terrain to reach the whaling station at Stromness on May 2. A relief ship collected the other three men and finally arrived back on Elephant Island in August. Miraculously, Shackleton’s entire crew was still alive.
Enlarge/ This is the stern of the good ship Endurance, which sank off the coast of Antarctica in 1915 after being crushed by pack ice. An expedition located the shipwreck in pristine condition in 2022 after nearly 107 years.
Falklands Maritime Heritage Trust/NatGeo
Shackleton’s last voyage
By the time Shackleton got back to England, the country was embroiled in World War I, and many of his men enlisted. Shackleton was considered too old for active service. He was also deeply in debt from the Endurance expedition, earning a living on the lecture circuit. But he still dreamed of making another expedition to the Arctic Ocean north of Alaska to explore the Beaufort Sea. He got seed money (and eventually full funding) from an old school chum, John Quillier Rowett. Shackleton purchased a wooden Norwegian whaler, Foca I, which his wife Emily renamed Quest.
The development of gene editing tools, which enable the specific targeting and correction of mutations, hold the promise of allowing us to correct those mutations that cause genetic diseases. However, the technology has been around for a while now—two researchers were critical to its development in 2020—and there have been only a few cases where gene editing has been used to target diseases.
One of the reasons for that is the challenge of targeting specific cells in a living organism. Many genetic diseases affect only a specific cell type, such as red blood cells in sickle-cell anemia, or specific tissue. Ideally, to limit potential side effects, we’d like to ensure that enough of the editing takes place in the affected tissue to have an impact, while minimizing editing elsewhere to limit side effects. But our ability to do so has been limited. Plus, a lot of the cells affected by genetic diseases are mature and have stopped dividing. So, we either need to repeat the gene editing treatments indefinitely or find a way to target the stem cell population that produces the mature cells.
On Thursday, a US-based research team said that they’ve done gene editing experiments that targeted a high-profile genetic disease: cystic fibrosis. Their technique largely targets the tissue most affected by the disease (the lung), and occurs in the stem cell populations that produce mature lung cells, ensuring that the effect is stable.
Getting specific
The foundation of the new work is the technology that gets the mRNAs of the COVID-19 mRNA vaccines inside cells. The nucleic acids of an mRNA are large molecules with a lot of charged pieces, which makes it difficult for them to cross a membrane to get inside of a cell. To overcome that problem, the researchers package the mRNA inside a bubble of lipids, which can then fuse with cell membranes, dumping the mRNA inside the cell.
This process, as the researchers note, has two very large advantages: We know it works, and we know it’s safe. “More than a billion doses of lipid nanoparticle–mRNA COVID-19 vaccines have been administered intramuscularly worldwide,” they write, “demonstrating high safety and efficacy sustained through repeatable dosing.” (As an aside, it’s interesting to contrast the research community’s view of the mRNA vaccines to the conspiracies that circulate widely among the public.)
There’s one big factor that doesn’t matter for vaccine delivery but does matter for gene editing: They’re not especially fussy about what cells they target for delivery. So, if you want to target something like blood stem cells, then you need to alter the lipid particles in some way to get them to preferentially target the cells of your choice.
There are a lot of ideas on how to do this, but the team behind this new work found a relatively simple one: changing the amount of positively charged lipids on the particle. In 2020, they published a paper in which they describe the development of selective organ targeting (SORT) lipid nanoparticles. By default, many of the lipid particles end up in the liver. But, as the fraction of positively charged lipids increases, the targeting shifts to the spleen and then to the lung.
So, presumably, because they know they can target the lung, they decided to use SORT particles to send a gene editing system specific to cystic fibrosis, which primarily affects that tissue and is caused by mutations in a single gene. While it’s relatively easy to get things into the lung, it’s tough to get them to lung cells, given all the mucus, cilia, and immune cells that are meant to take care of foreign items in the lung.
Enlarge/ Ten milligram tablets of the hyperactivity drug, Adderall, made by Shire Plc, is shown in a Cambridge, Massachusetts pharmacy Thursday, January 19, 2006.
The Centers for Disease Control and Prevention on Thursday warned that a federal indictment of an allegedly fraudulent telehealth company may lead to a massive, nationwide disruption in access to ADHD medications—namely Adderall, but also other stimulants—and could possibly increase the risk of injuries and overdoses.
“A disruption involving this large telehealth company could impact as many as 30,000 to 50,000 patients ages 18 years and older across all 50 US states,” the CDC wrote in its health alert.
The CDC warning came on the heels of an announcement from the Justice Department Thursday that federal agents had arrested two people in connection with an alleged scheme to illegally distribute Adderall and other stimulants through a subscription-based online telehealth company called Done Global. The company’s CEO and founder, Ruthia He, was arrested in Los Angeles, and its clinical president, David Brody, was arrested in San Rafael, California.
“As alleged, these defendants exploited the COVID-19 pandemic to develop and carry out a $100 million scheme to defraud taxpayers and provide easy access to Adderall and other stimulants for no legitimate medical purpose,” Attorney General Merrick Garland said in a statement. “Those seeking to profit from addiction by illegally distributing controlled substances over the Internet should know that they cannot hide their crimes and that the Justice Department will hold them accountable.”
Deadly consequences
According to the Justice Department, Done Global generated $100 million in revenue by arranging for the prescription of over 40 million pills of Adderall and other stimulants, which are addictive medications used to treat ADHD (attention-deficit/hyperactivity disorder). Done Global allegedly eased access to the drugs by limiting the information available to prescribers, instructing prescribers to prescribe Adderall and other stimulants even if the patient didn’t qualify, and mandating that the prescribing appointments last no longer than 30 minutes. The company also discouraged prescriber follow-up appointments and added an “auto-refill” feature.
Prosecutors further allege that He and Brody continued with their scheme after becoming aware that patients had overdosed and died.
The CDC cautioned that the disruption from lost access to Done Global prescriptions comes amid a long-standing, nationwide shortage of Adderall and other stimulant medications. For patients with ADHD, the disruption could be harmful. “Untreated ADHD is associated with adverse outcomes, including social and emotional impairment, increased risk of drug or alcohol use disorder, unintentional injuries, such as motor vehicle crashes, and suicide,” the CDC warns. Further, a loss of access could drive some to seek illicit sources of the drugs, which could turn deadly.
“Patients whose care or access to prescription stimulant medications is disrupted, and who seek medication outside of the regulated healthcare system, might significantly increase their risk of overdose due to the prevalence of counterfeit pills in the illegal drug market that could contain unexpected substances, including fentanyl,” the CDC said. Fentanyl is a synthetic opioid that is up to 50 times stronger than heroin and 100 times stronger than morphine.
The Drug Enforcement Administration recently reported that seven out of every 10 pills seized from the illegal drug market contain a potentially lethal dose of illegally made fentanyl, the CDC noted.
This post was updated to clarify that the DEA’s data indicated that 70 percent of illicit pills seized contained “potentially” lethal doses, which was not included in the CDC’s warning.
